John P Marinelli1, Brandon R Grossardt2, Christine M Lohse2, Matthew L Carlson3,4. 1. Mayo Clinic School of Medicine. 2. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research. 3. Department of Otolaryngology-Head and Neck Surgery. 4. Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota.
Abstract
OBJECTIVE: Reported epidemiologic data surrounding vestibular schwannoma (VS) are controversial. Temporal bone prevalence studies have suggested that VS affects up to 2.4% of the population, whereas magnetic resonance imaging (MRI) studies have reported VS to affect 0.017%. Moreover, existing population-based data seem to underestimate the commonness of VS. In an attempt to reconcile temporal bone, radiologic, and population-based reports regarding VS, the current study was conceived to determine the modern prevalence of VS using a unique epidemiological database. PATIENTS: All persons living in Olmsted County, Minnesota on January 1, 2017 with a confirmed diagnosis of sporadic VS identified using the Rochester Epidemiology Project (REP) medical records-linkage system. MAIN OUTCOME MEASURES: Prevalence of all VS and asymptomatic, incidentally diagnosed VS. RESULTS: Sixty-seven persons from a population of nearly 160,000 were living with VS on January 1, 2017, resulting in a point prevalence of 42.0 per 100,000 persons. The prevalence increased with older age, reaching 212.4 per 100,000 in those ≥ 70 years. Including only persons who have undergone head MRI, the prevalence of asymptomatic, incidentally diagnosed VS was 69.9 per 100,000 among adults age 20 years and older. CONCLUSIONS: Using the unique infrastructure of the REP, the current study suggests that the clinical prevalence of sporadic VS approximates 1 in 2,000 adults and 1 in every 500 persons aged 70 years and older, with the prevalence of incidentally diagnosed tumors closely paralleling past MRI studies. These data characterize a shift in the modern patient demographic of sporadic VS, as now many people bearing a diagnosis of VS would have previously died without knowledge of their disease. Moreover, they typify an unfolding transition from an era of microsurgery and radiosurgery to the beginnings of an era that will be largely comprised of "chronic disease management."
OBJECTIVE: Reported epidemiologic data surrounding vestibular schwannoma (VS) are controversial. Temporal bone prevalence studies have suggested that VS affects up to 2.4% of the population, whereas magnetic resonance imaging (MRI) studies have reported VS to affect 0.017%. Moreover, existing population-based data seem to underestimate the commonness of VS. In an attempt to reconcile temporal bone, radiologic, and population-based reports regarding VS, the current study was conceived to determine the modern prevalence of VS using a unique epidemiological database. PATIENTS: All persons living in Olmsted County, Minnesota on January 1, 2017 with a confirmed diagnosis of sporadic VS identified using the Rochester Epidemiology Project (REP) medical records-linkage system. MAIN OUTCOME MEASURES: Prevalence of all VS and asymptomatic, incidentally diagnosed VS. RESULTS: Sixty-seven persons from a population of nearly 160,000 were living with VS on January 1, 2017, resulting in a point prevalence of 42.0 per 100,000 persons. The prevalence increased with older age, reaching 212.4 per 100,000 in those ≥ 70 years. Including only persons who have undergone head MRI, the prevalence of asymptomatic, incidentally diagnosed VS was 69.9 per 100,000 among adults age 20 years and older. CONCLUSIONS: Using the unique infrastructure of the REP, the current study suggests that the clinical prevalence of sporadic VS approximates 1 in 2,000 adults and 1 in every 500 persons aged 70 years and older, with the prevalence of incidentally diagnosed tumors closely paralleling past MRI studies. These data characterize a shift in the modern patient demographic of sporadic VS, as now many people bearing a diagnosis of VS would have previously died without knowledge of their disease. Moreover, they typify an unfolding transition from an era of microsurgery and radiosurgery to the beginnings of an era that will be largely comprised of "chronic disease management."
Authors: Saumil N Merchant; Michael J McKenna; Joe C Adams; Joseph B Nadol; Jose Fayad; Robert Gellibolian; Fred H Linthicum; Akira Ishiyama; Ivan Lopez; Gail Ishiyama; Robert Baloh; Christopher Platt Journal: Otol Neurotol Date: 2008-04 Impact factor: 2.311
Authors: Richard F Schmidt; Zain Boghani; Osamah J Choudhry; Jean Anderson Eloy; Robert W Jyung; James K Liu Journal: Neurosurg Focus Date: 2012-09 Impact factor: 4.047
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Am J Epidemiol Date: 2011-03-23 Impact factor: 4.897
Authors: Piyameth Dilokthornsakul; Robert J Valuck; Kavita V Nair; John R Corboy; Richard R Allen; Jonathan D Campbell Journal: Neurology Date: 2016-02-17 Impact factor: 9.910
Authors: Walter A Rocca; Barbara P Yawn; Jennifer L St Sauver; Brandon R Grossardt; L Joseph Melton Journal: Mayo Clin Proc Date: 2012-11-28 Impact factor: 7.616
Authors: Satoshi Kiyofuji; Brian A Neff; Matthew L Carlson; Colin L W Driscoll; Michael J Link Journal: Acta Neurochir (Wien) Date: 2021-01-20 Impact factor: 2.216
Authors: Erin Cohen; Stefanie Pena; Christine Mei; Olena Bracho; Brian Marples; Nagy Elsayyad; Stefania Goncalves; Michael Ivan; Paula V Monje; Xue-Zhong Liu; Cristina Fernandez-Valle; Fred Telischi; Christine T Dinh Journal: J Neurol Surg B Skull Base Date: 2021-01-19
Authors: Matthias A Karajannis; Audrey Mauguen; Ekrem Maloku; Qingwen Xu; Erin M Dunbar; Scott R Plotkin; Anna Yaffee; Shiyang Wang; J Thomas Roland; Chandranath Sen; Dimitris G Placantonakis; John G Golfinos; Jeffrey C Allen; Nicholas A Vitanza; Luis A Chiriboga; Robert J Schneider; Jingjing Deng; Thomas A Neubert; Judith D Goldberg; David Zagzag; Filippo G Giancotti; Jaishri O Blakeley Journal: Mol Cancer Ther Date: 2021-06-17 Impact factor: 6.261
Authors: John P Marinelli; Christine M Lohse; Brandon R Grossardt; John I Lane; Matthew L Carlson Journal: Otol Neurotol Date: 2020-07 Impact factor: 2.619
Authors: John P Marinelli; Ashley M Nassiri; Elizabeth B Habermann; Christine M Lohse; Sara J Holton; Matthew L Carlson Journal: Otol Neurotol Date: 2021-07-01 Impact factor: 2.619
Authors: Mohamed H Khattab; Alexander D Sherry; Nauman Manzoor; Douglas J Totten; Guozhen Luo; Lola B Chambless; Alejandro Rivas; David S Haynes; Anthony J Cmelak; Albert Attia Journal: J Neurol Surg B Skull Base Date: 2020-05-26
Authors: John P Marinelli; Douglas J Totten; Kiran K Chauhan; Christine M Lohse; Brandon R Grossardt; Jeffrey T Vrabec; Matthew L Carlson Journal: Otol Neurotol Date: 2020-10 Impact factor: 2.619